Overview

Opioid-Free Pain Protocol After Shoulder Arthroplasty

Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
0
Participant gender:
All
Summary
This randomized, single blinded, clinical trial aims to investigate the efficacy of a multimodal pain control regimen for shoulder arthroplasty. Patients who receive a multimodal pain control regimen alone (study group) will be compared to patients who receive a multimodal pain control regimen plus a standard prescription of an opioid containing medication (comparison group). The primary outcome is average daily Numerical Rating Scale (NRS) pain score in the first 10 days after surgery. We hypothesize that there will be no significant difference in the primary outcome between the two groups.
Phase:
Phase 4
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Henry Ford Health System
Treatments:
Acetaminophen
Celecoxib
Dexamethasone
Epinephrine
Ibuprofen
Ketorolac
Oxycodone
Pregabalin
Tizanidine
Tramadol
Criteria
Inclusion Criteria:

- Consented and scheduled for primary anatomic or reverse total shoulder arthroplasty at
a Henry Ford hospital location

Exclusion Criteria:

- Unable to receive or reply to mobile phone text messages.

- Unable to read or speak English

- Medical history of known allergies or intolerance to any of the medications prescribed
as a part of this study (ie, Percocet, Ibuprofen, Pregabalin, Dexamethasone,
Acetaminophen, Tizanidine, Magnesium, Celecoxib, Tramadol, Ropivacaine, Epinephrine,
Ketorolac)

- Substantial alcohol or drug abuse

- Recent or current pregnancy

- History of narcotic use within 3 months prior to surgery

- Renal or hepatic impairment or dysfunction

- Use of blood thinner medication

- Peptic ulcer disease

- Gastrointestinal bleeding

- History of gastric bypass surgery